SomnoMed Past Earnings Performance

Past criteria checks 0/6

SomnoMed's earnings have been declining at an average annual rate of -60.8%, while the Medical Equipment industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 10.5% per year.

Key information

-60.8%

Earnings growth rate

-56.4%

EPS growth rate

Medical Equipment Industry Growth5.8%
Revenue growth rate10.5%
Return on equity-27.2%
Net Margin-13.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

SomnoMed Limited (ASX:SOM) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 02
SomnoMed Limited (ASX:SOM) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Benign Growth For SomnoMed Limited (ASX:SOM) Underpins Stock's 27% Plummet

Oct 16
Benign Growth For SomnoMed Limited (ASX:SOM) Underpins Stock's 27% Plummet

SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

Jul 15
SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

May 31
SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Apr 15
SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Mar 04
SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)

Dec 21
Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)

SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks

Sep 02
SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks

Is SomnoMed (ASX:SOM) Using Too Much Debt?

Jun 19
Is SomnoMed (ASX:SOM) Using Too Much Debt?

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

Nov 18
It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Sep 27
SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

May 10
Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Oct 26
Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

May 12
Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

Mar 02
Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Feb 01
Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Dec 28
Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Dec 01
Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Analysts Just Published A Bright New Outlook For SomnoMed Limited's (ASX:SOM)

Jul 28
Analysts Just Published A Bright New Outlook For SomnoMed Limited's (ASX:SOM)

SomnoMed Limited (ASX:SOM) Insiders Increased Their Holdings

Jul 14
SomnoMed Limited (ASX:SOM) Insiders Increased Their Holdings

Revenue & Expenses Breakdown

How SomnoMed makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:SOM Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2492-12580
31 Mar 2490-11560
31 Dec 2389-11560
30 Sep 2386-9530
30 Jun 2384-8500
31 Mar 2381-7490
31 Dec 2279-5480
30 Sep 2276-5460
30 Jun 2273-4440
31 Mar 2269-5430
31 Dec 2166-5410
30 Sep 2164-3380
30 Jun 2163-1350
31 Mar 2159-1320
31 Dec 2055-1300
30 Sep 2056-1300
30 Jun 20570310
31 Mar 20600320
31 Dec 19631330
30 Sep 19610320
30 Jun 19590320
31 Mar 19582320
31 Dec 18563310
30 Sep 18543300
30 Jun 18522290
31 Mar 1851-1300
31 Dec 1750-4320
30 Sep 1750-4320
30 Jun 1749-3310
31 Mar 1748-2290
31 Dec 1647-1260
30 Sep 16450250
30 Jun 16440240
31 Mar 16420230
31 Dec 15391210
30 Sep 15371200
30 Jun 15341190
31 Mar 15341180
31 Dec 14351180
30 Sep 14321170
30 Jun 14300160
31 Mar 14260150
31 Dec 13220140

Quality Earnings: SOM is currently unprofitable.

Growing Profit Margin: SOM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SOM is unprofitable, and losses have increased over the past 5 years at a rate of 60.8% per year.

Accelerating Growth: Unable to compare SOM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SOM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.7%).


Return on Equity

High ROE: SOM has a negative Return on Equity (-27.19%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SomnoMed Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightAPP Securities Pty Ltd.
Peter MeichelboeckSelect Equities Pty Ltd
Dr StoreyWilsons Advisory and Stockbroking Ltd.